450 related articles for article (PubMed ID: 29160853)
1. Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.
Hui KF; Tam KP; Chiang AKS
Viruses; 2017 Nov; 9(11):. PubMed ID: 29160853
[TBL] [Abstract][Full Text] [Related]
2. Estimating the global burden of Epstein-Barr virus-related cancers.
Wong Y; Meehan MT; Burrows SR; Doolan DL; Miles JJ
J Cancer Res Clin Oncol; 2022 Jan; 148(1):31-46. PubMed ID: 34705104
[TBL] [Abstract][Full Text] [Related]
3. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of Epstein-Barr virus from latency.
Amon W; Farrell PJ
Rev Med Virol; 2005; 15(3):149-56. PubMed ID: 15546128
[TBL] [Abstract][Full Text] [Related]
5. Curcumin Inhibits Proliferation of Epstein-Barr Virus-Associated Human Nasopharyngeal Carcinoma Cells by Inhibiting EBV Nuclear Antigen 1 Expression.
Liu L; Yang J; Ji W; Wang C
Biomed Res Int; 2019; 2019():8592921. PubMed ID: 31687403
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Hui KF; Chiang AK
Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus and cancers of the head and neck.
Goldenberg D; Golz A; Netzer A; Rosenblatt E; Rachmiel A; Goldenberg RF; Joachims HZ
Am J Otolaryngol; 2001; 22(3):197-205. PubMed ID: 11351290
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
9. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-associated lymphoproliferative disorders.
Grywalska E; Markowicz J; Grabarczyk P; Pasiarski M; Roliński J
Postepy Hig Med Dosw (Online); 2013 May; 67():481-90. PubMed ID: 23752600
[TBL] [Abstract][Full Text] [Related]
11. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
Chiang AK; Tao Q; Srivastava G; Ho FC
Int J Cancer; 1996 Nov; 68(3):285-90. PubMed ID: 8903467
[TBL] [Abstract][Full Text] [Related]
12. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
13. The biological properties of different Epstein-Barr virus strains explain their association with various types of cancers.
Tsai MH; Lin X; Shumilov A; Bernhardt K; Feederle R; Poirey R; Kopp-Schneider A; Pereira B; Almeida R; Delecluse HJ
Oncotarget; 2017 Feb; 8(6):10238-10254. PubMed ID: 28052012
[TBL] [Abstract][Full Text] [Related]
14. Sequence variation of Epstein-Barr virus (EBV) BCRF1 in lymphomas in non-endemic areas of nasopharyngeal carcinoma.
Han L; Sun L; Zhao Z; Chao Y; Sun Z; Li H; Luo B
Arch Virol; 2015 Feb; 160(2):441-5. PubMed ID: 25373543
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Novalić Z; Verkuijlen SAWM; Verlaan M; Eersels JLH; de Greeuw I; Molthoff CFM; Middeldorp JM; Greijer AE
J Med Virol; 2017 Dec; 89(12):2207-2216. PubMed ID: 28853217
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus: 40 years on.
Young LS; Rickinson AB
Nat Rev Cancer; 2004 Oct; 4(10):757-68. PubMed ID: 15510157
[TBL] [Abstract][Full Text] [Related]
17. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus (EBV) and human disease: facts, opinions and problems.
Griffin BE
Mutat Res; 2000 Apr; 462(2-3):395-405. PubMed ID: 11523539
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma.
Shah KM; Young LS
Clin Microbiol Infect; 2009 Nov; 15(11):982-8. PubMed ID: 19874382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
